---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-092475"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:15:01.234544+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex to acquire Alpine Immune Sciences for $65 per share in all-cash tender offer

## Summary
- Vertex agrees to buy Alpine Immune Sciences at $65/share via tender offer followed by a merger.
- Supporting stockholders owning ~25.5% of Alpine shares have committed to tender their shares.
- Alpine must pay Vertex a $173M termination fee if deal terminates under specified conditions.
- Offer is not subject to a financing condition; expected to close by April 10, 2025 outside date.
- Deal includes full vesting of unvested equity awards, which will be cashed out at the offer price.

## SEC filing metadata
- accession: 0001193125-24-092475
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/d752930d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-092475
- JSON: https://secwatch.observer/filing/0001193125-24-092475.json
- Plain text: https://secwatch.observer/filing/0001193125-24-092475.txt

## Key facts
- Material Agreements
  VERTEX PHARMACEUTICALS INC / MA entered into Agreement and Plan of Merger with Alpine Immune Sciences, Inc. valued at $65.00 per share (effective 2024-04-10).
  - Action: entry
  - Agreement: merger
  - Counterparty: Alpine Immune Sciences, Inc.
  - Value: $65.00 per share
  - Effective: 2024-04-10
  source text: On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.